Mirum Pharmaceuticals, Inc. (MIRM) incurred second-quarter 2024 loss of 52 cents per share, wider than the Zacks Consensus Estimate of a loss of 48 cents. The company had reported a loss of 92 cents per share in the year-ago quarter. Revenues in the second quarter totaled $77.9 million, up almost 107.7% year over year. The figure beat the Zacks Consensus Estimate of $75 million. The top line comprised Livmarli (maralixibat) sales, newly acquired Cholbam and Chenodal sales and minimal license and other reven ...